Literature DB >> 21295334

Celiac lymph node resection and porta hepatis disease resection in advanced or recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.

A Martinez1, C Pomel, E Mery, D Querleu, L Gladieff, G Ferron.   

Abstract

INTRODUCTION: Prognostic value of complete macroscopic resection of primary disease has been reported and confirmed in several publications. Published data indicate that extensive upper abdominal disease involving the hepatic pedicle and celiac trunk is associated with an abortion of the surgical procedure or with suboptimal residual disease.
METHODS: All patients who had disease at the porta hepatis or celiac lymph node resection as part of cytoreductive surgery were included. Medical and operative records with particular emphasis on extent and distribution of disease spread, number of peritonectomy procedures, visceral resections, and lymphadenectomy procedures were examined.
RESULTS: A total of 28 patients who underwent some kind of celiac lymph node resection or resection of metastatic involvement of the porta hepatis were included. Median preoperative serum Ca-125 level was 78U/ml (range, 30-2950U/ml), and median ascites volume was 1900ml (range, 0-10,000ml). Of the 28 patients, 23 underwent supra-radical surgery for diffuse peritoneal carcinomatosis. Median operative time was 252minutes (range, 100-540minutes). Complete cytoreduction to CCO was achieved in all except one case, who was cytoreduced to millimetric residue. Fifteen patients had positive celiac nodes and nineteen patients had peritoneal disease in the porta hepatis region. DISCUSSION: Resection of enlarged nodes and metastatic disease to the porta hepatis is feasible with an acceptable morbidity. The decision to undergo an aggressive cytoreductive surgery is based on appropriate patient selection depending on the extension of surgical procedure, on medical comorbidities, and on the potential to tolerate an extensive procedure, rather than on specific anatomic locations.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21295334     DOI: 10.1016/j.ygyno.2010.12.328

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

1.  Right Upper Abdominal Resections in Advanced Stage Ovarian Cancer.

Authors:  Nicolae Bacalbasa; Camelia Diaconu; Laura Iliescu; Alexandru Filipescu; Irina Balescu; Cora Pop; Simona Dima; Mihaela Vilcu; Iulian Brezean
Journal:  In Vivo       Date:  2020-04-29       Impact factor: 2.155

Review 2.  Cholecystectomy, porta hepatis stripping, and omental bursectomy.

Authors:  Joo-Hyuk Son; Suk-Joon Chang
Journal:  Gland Surg       Date:  2021-03

Review 3.  Novel Surgical Strategies in the Treatment of Gynecological Malignancies.

Authors:  Martina Aida Angeles; Carlos Martínez-Gómez; Federico Migliorelli; Marie Voglimacci; Justine Figurelli; Stephanie Motton; Yann Tanguy Le Gac; Gwénaël Ferron; Alejandra Martinez
Journal:  Curr Treat Options Oncol       Date:  2018-11-09

Review 4.  Radical surgery in ovarian cancer.

Authors:  Deepa Maheswari Narasimhulu; Fady Khoury-Collado; Dennis S Chi
Journal:  Curr Oncol Rep       Date:  2015-04       Impact factor: 5.075

5.  Minimally Invasive Secondary Cytoreductive Surgery for Superficial Celiac and Cardio-Phrenic Isolated Nodal Recurrence of Ovarian Cancer.

Authors:  M Loverro; R Ergasti; C Conte; V Gallitelli; D Nachira; G Scaglione; A Fagotti; G Scambia; V Gallotta
Journal:  Ann Surg Oncol       Date:  2022-01-08       Impact factor: 5.344

Review 6.  Hepatic Hilar Lymph Node Resection in Cytoreductive Surgery for Advanced Ovarian Cancer: A Necessity or Not?

Authors:  Honglian Huang; Renjie Wei; Ying Long; Yu Mo; Yu Xie; Desheng Yao
Journal:  Cancer Manag Res       Date:  2021-10-20       Impact factor: 3.989

7.  Hepatobiliary Disease Resection in Patients with Advanced Epithelial Ovarian Cancer: Prognostic Role and Optimal Cytoreduction.

Authors:  Violante Di Donato; Andrea Giannini; Ottavia D'Oria; Michele Carlo Schiavi; Anna Di Pinto; Margherita Fischetti; Francesca Lecce; Giorgia Perniola; Francesco Battaglia; Pasquale Berloco; Ludovico Muzii; Pierluigi Benedetti Panici
Journal:  Ann Surg Oncol       Date:  2020-08-10       Impact factor: 5.344

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.